Vitiligo is a chronic skin condition in which the body’s immune system destroys the cells that produce skin color, leaving behind smooth white patches. It affects an estimated 28.5 million people worldwide, with a global prevalence of about 0.36%. The word itself comes from Latin, first recorded in the first century AD by the Roman physician Celsus in his medical text De Medicina. Its exact root is debated, but scholars have linked it to Latin words like vitium (meaning defect or flaw) and vitelius or vituli, which compared the white patches to markings seen on calves.
What Happens Inside the Skin
Your skin gets its color from melanocytes, specialized cells that produce the pigment melanin. In vitiligo, the immune system mistakenly identifies these cells as threats and destroys them. The process unfolds in stages. First, environmental triggers like UV radiation, chemical exposure, physical trauma, pregnancy, or emotional stress cause a buildup of harmful molecules called reactive oxygen species inside melanocytes. This overwhelms the cells’ natural defenses and damages their internal structures.
That initial stress exposes pieces of the melanocyte to the immune system, essentially flagging them as foreign. The body’s immune response then escalates. A specific type of immune cell, CD8+ T cells, delivers the final blow, killing melanocytes through the same mechanisms the body uses to destroy virus-infected cells. Once the melanocytes in an area are gone, the skin loses its ability to produce pigment there, and a white patch forms.
First Signs and Common Locations
The earliest sign is typically a small, pale patch that stands out from surrounding skin. These patches usually appear first on the hands, face, and areas around body openings like the eyes, nostrils, mouth, and genitals. Some people also notice premature whitening or graying of hair on the scalp, eyebrows, eyelashes, or beard. In some cases, the tissues lining the inside of the mouth and nose lose color too.
The patches are painless and flat. They don’t itch, flake, or change texture. The skin itself is healthy; it simply has no pigment. On lighter skin tones, vitiligo can be subtle at first and may only become obvious after sun exposure, when the contrast between tanned and depigmented skin increases.
Types and How They Progress
Vitiligo falls into two main categories, and knowing which type you have matters because they behave differently.
Non-segmental vitiligo is the most common form. It tends to appear symmetrically on both sides of the body and typically spreads over time, though the pace varies widely. It may start as a few patches on the face or hands and later progress to larger areas. Subtypes include acrofacial (limited to the face and extremities), generalized (widespread), and universal (affecting most of the body).
Segmental vitiligo behaves quite differently. It affects one side or one section of the body, spreads rapidly within that area over 6 to 24 months, and then usually stops. Further extension beyond that segment is rare.
Some people develop both types, a combination called mixed vitiligo. And when a person has just a single small patch that hasn’t clearly fit either pattern after one to two years of observation, dermatologists classify it as focal vitiligo.
How Vitiligo Is Diagnosed
Diagnosis is primarily visual. A dermatologist examines the skin, often using a Wood’s lamp, a handheld ultraviolet light that makes depigmented areas glow bright white against normal skin. This is especially useful for detecting patches on fair skin that might be hard to see in regular light. The lamp also helps distinguish vitiligo from other conditions that cause lighter spots, because fully depigmented skin (with no melanocytes at all) looks different under UV light than skin that simply has reduced pigment.
Dermatologists also look at the borders of each patch. Active, spreading vitiligo tends to have fuzzy, poorly defined edges, while stable patches typically show sharp, well-defined borders. This distinction helps guide treatment decisions.
Linked Health Conditions
Because vitiligo is autoimmune, it often travels with other autoimmune conditions. The most common companion is autoimmune thyroid disease, a connection documented across decades of research. People with vitiligo are also more likely to have type 1 diabetes, pernicious anemia, rheumatoid arthritis, psoriasis, inflammatory bowel disease, or lupus. This doesn’t mean everyone with vitiligo will develop these conditions, but it’s worth being aware of, particularly regarding thyroid function.
One common fear that the evidence doesn’t support: skin cancer. A systematic review and meta-analysis found no statistically significant increase in melanoma, non-melanoma skin cancer, or lymphoma among people with vitiligo. Some data even suggested a possible protective effect against certain skin cancers, likely because the same immune activity that destroys melanocytes may also be effective at targeting abnormal cells.
Treatment Options
For decades, vitiligo treatment was limited to light therapy and topical steroids, both of which work for some people but produce inconsistent results. That changed in 2022 when the FDA approved the first pharmacologic treatment specifically for repigmentation: a topical cream containing ruxolitinib, a JAK inhibitor. It works by dialing down the immune signals that drive melanocyte destruction, giving surviving or newly migrating melanocytes a chance to repopulate the skin.
In clinical trials, 30% of patients using the cream achieved at least 75% improvement in facial vitiligo scores after 24 weeks, compared to 10% on placebo. It’s approved for non-segmental vitiligo in patients 12 and older. Results are most noticeable on the face, which tends to respond better than hands or feet because of a richer supply of melanocyte stem cells in facial hair follicles.
Light therapy, particularly narrowband UVB, remains a mainstay and is often combined with topical treatments. For stable segmental vitiligo that has stopped spreading, surgical options like epidermal grafting can transplant healthy melanocytes into depigmented areas.
Emotional and Social Impact
Vitiligo is medically benign, but its psychological weight is real. In one study of vitiligo patients at a teaching hospital, 59% met criteria for depression, with 53% experiencing mild depression and 6% moderate depression. Eight percent reported suicidal thoughts. Sleep difficulties were reported by 89% of patients, compared to 38% of people without the condition.
The emotional burden comes largely from visibility. People with vitiligo commonly report embarrassment, low self-esteem, and social withdrawal, particularly when patches appear on the face, hands, or other exposed areas. The sense of being stigmatized can interfere with relationships, work, and everyday social interactions. Women, especially in cultures where skin appearance carries social consequences, tend to report a greater impact on quality of life. The unpredictable nature of the disease, not knowing whether patches will spread, stay stable, or respond to treatment, adds its own layer of psychological strain.